title: Pixantrone (Novuspharma).
abstract: Novuspharma is developing pixantrone, a second-generation, well-tolerated anthracenedione analog, for the potential treatment of lymphoma and multiple sclerosis.
authors.affiliation: University of Cologne, First Department of Internal Medicine, Joseph-Stelzmann Strasse 9, 50924 Koeln, Germany. peter.borchmann@uni-koeln.de
authors.forename: Peter
authors.initials: P
authors.lastname: Borchmann
authors.forename: Marcel
authors.initials: M
authors.lastname: Reiser
mesh_terms: D000818:Animals; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D007546:Isoquinolines / Q000737:chemistry / Q000627:therapeutic use*; D013678:Technology, Pharmaceutical / Q000331:legislation & jurisprudence / Q000379:methods* / Q000639:trends; D059005:Topoisomerase II Inhibitors
chemical_list: D007546:Isoquinolines; D059005:Topoisomerase II Inhibitors; C086548:pixantrone